Skip to main content
SpringerLink
Log in

A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Treatment guidelines generally recommend careful assessment and non-pharmacological treatment approaches for behavioural and psychological symptoms of dementia. However, the inappropriate use of psychoactive drugs in patients with dementia in nursing homes is still prevalent. The aim of this narrative review is to summarise and criticize the most recent data investigating the adverse outcomes related to psychoactive drug use, specifically antipsychotics, antidepressants and benzodiazepines, in patients with dementia living in nursing homes. Searches of PubMed® and Web of Science® identified 790 potentially relevant articles, 23 of which were retained in this review. All studies investigated adverse outcomes of antipsychotics compared with non-use, or with antidepressants and/or benzodiazepine anxiolytic or hypnotic drugs. Several studies focused on the comparison between atypical and conventional antipsychotics, risperidone often being the reference. The most frequently reported outcomes were mortality (all-cause or cardiovascular), falls and/or fractures, and cardiovascular or cerebrovascular events. Overall, for mortality or falls, the highest risk is for benzodiazepines, followed by conventional antipsychotics, antidepressants and atypical antipsychotics. Whatever the drug, the patient must be carefully monitored during the first days of treatment, which needs to be initiated at the lowest possible dose and for the shortest duration. In light of the high risk of adverse outcomes (falls, cardiovascular events, infections, mortality) for patients with dementia living in nursing homes, all drugs must be carefully prescribed. However, further studies comparing pharmacological with non-pharmacological interventions, with a realistic consideration of the structural nursing home organisation, would be welcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Laffon de Mazieres C, Lapeyre-Mestre M, Vellas B, et al. Organizational factors associated with inappropriate neuroleptic drug prescribing in nursing homes: a multilevel approach. J Am Med Dir Assoc. 2015;16(7):590–7. doi:10.1016/j.jamda.2015.01.092.

    Article  PubMed  Google Scholar 

  2. Cool C, Cestac P, Laborde C, et al. Potentially inappropriate drug prescribing and associated factors in nursing homes. J Am Med Dir Assoc. 2014;15(11):850.e1–9. doi:10.1016/j.jamda.2014.08.003.

    Article  Google Scholar 

  3. Barreto PD, Lapeyre-Mestre M, Mathieu C, et al. Indicators of benzodiazepine use in nursing home residents in France: a cross-sectional study. J Am Med Dir Assoc. 2013;14(1):29–33. doi:10.1016/j.jamda.2012.09.002.

    Article  Google Scholar 

  4. Montastruc F, Gardette V, Cantet C, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs! Eur J Clin Pharmacol. 2013;69(8):1589–97. doi:10.1007/s00228-013-1506-8.

    Article  PubMed  Google Scholar 

  5. Ruths S, Sorensen PH, Kirkevold O, et al. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. Int J Geriatr Psychiatry. 2013;28(8):868–76. doi:10.1002/gps.3902.

    Article  PubMed  Google Scholar 

  6. Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–97.

    Article  CAS  PubMed  Google Scholar 

  7. Wei YJ, Simoni-Wastila L, Zuckerman IH, et al. Quality of psychopharmacological medication prescribing and mortality in Medicare beneficiaries in nursing homes. J Am Geriatr Soc. 2014;62(8):1490–504. doi:10.1111/jgs.12939.

    Article  PubMed  Google Scholar 

  8. Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68(5):833–44. doi:10.1007/s00228-011-1188-z.

    Article  CAS  PubMed  Google Scholar 

  9. Iaboni A, Bronskill SE, Reynolds KB, et al. Changing pattern of sedative use in older adults: a population-based cohort study. Drug Aging. 2016;33(7):523–33. doi:10.1007/s40266-016-0380-3.

    Article  CAS  Google Scholar 

  10. Johnson CF, Frei C, Downes N, et al. Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population-based study. Br J Gen Pract. 2016;66(647):e410–5. doi:10.3399/bjgp16X685213.

    Article  PubMed  Google Scholar 

  11. Lapane KL, Hume A, Ulbricht C, Gambassi G. Safety of psychotropic drugs in the elderly. In: Spina E, Trifirò G, editors. Pharmacovigilance in psychiatry. Switzerland: Springer; 2016. p. 285–97.

    Chapter  Google Scholar 

  12. Manson C, Gordon R, Baldwin D. Safety and tolerability of antidepressants. In: Spina E, Trifirò G, editors. Pharmacovigilance in psychiatry. Switzerland: Springer; 2016. p. 149–66.

    Chapter  Google Scholar 

  13. Jann MW, Kennedy WK. Safety and tolerability of antipsychotics. In: Spina E, Trifirò G, editors. Pharmacovigilance in psychiatry. Switzerland: Springer; 2016. p. 167–89.

    Chapter  Google Scholar 

  14. Arcoraci V, Spina E. Safety and tolerability of anxiolytics/sedative-hypnotics. In: Spina E, Trifirò G, editors. Pharmacovigilance in psychiatry. Switzerland: Springer; 2016. p. 191–207.

    Chapter  Google Scholar 

  15. Bueno-Cavanillas A, Padilla-Ruiz F, Jimenez-Moleon JJ, et al. Risk factors in falls among the elderly according to extrinsic and intrinsic precipitating causes. Eur J Epidemiol. 2000;16(9):849–59. doi:10.1023/A:1007636531965.

    Article  CAS  PubMed  Google Scholar 

  16. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17(3):429–41. doi:10.1017/S1041610205002243.

    Article  PubMed  Google Scholar 

  17. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677–82. doi:10.1001/archinte.165.22.2677.

    Article  PubMed  Google Scholar 

  18. Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.

    Article  PubMed  Google Scholar 

  19. Raivio MM, Laurila JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriat Psychiat. 2007;15(5):416–24. doi:10.1097/JGP.0b013e31802d0b00.

    Article  Google Scholar 

  20. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007;68(6):929–34.

    Article  CAS  PubMed  Google Scholar 

  21. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090–6. doi:10.1001/archinte.168.10.1090.

    Article  PubMed  Google Scholar 

  22. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340–7. doi:10.4088/JCP.08m04597yel.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Simoni-Wastila L, Ryder PT, Qian J, et al. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17(5):417–27. doi:10.1097/JGP.0b013e31819b8936.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc. 2010;11(2):120–7. doi:10.1016/j.jamda.2009.10.001.

    Article  PubMed  Google Scholar 

  25. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411–9. doi:10.1503/cmaj.101406.

    PubMed  PubMed Central  Google Scholar 

  26. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977. doi:10.1136/bmj.e977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sterke CS, van Beeck EF, van der Velde N, et al. New insights dose-response relationship between psychotropic drugs and falls: a study in nursing home residents with dementia. J Clin Pharmacol. 2012;52(6):947–55. doi:10.1177/0091270011405665.

    Article  CAS  PubMed  Google Scholar 

  28. Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60(3):420–9. doi:10.1111/j.1532-5415.2011.03853.x.

    Article  PubMed  PubMed Central  Google Scholar 

  29. van de Ven-Vakhteeva J, Bor H, Wetzels RB, et al. The impact of antipsychotics and neuropsychiatric symptoms on the quality of life of people with dementia living in nursing homes. Int J Geriatr Psychiatry. 2013;28(5):530–8. doi:10.1002/gps.3858.

    Article  PubMed  Google Scholar 

  30. Dutcher SK, Rattinger GB, Langenberg P, et al. Effect of medications on physical function and cognition in nursing home residents with dementia. J Am Geriatr Soc. 2014;62(6):1046–55. doi:10.1111/jgs.12838.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Aparasu RR, Chatterjee S, Chen H. Risk of hospitalization and use of first-versus second-generation antipsychotics among nursing home residents. Psychiat Serv. 2014;65(6):781–8. doi:10.1176/appi.ps.201300093.

    Article  Google Scholar 

  32. Huang TY, Wei YJ, Moyo P, et al. Treated behavioral symptoms and mortality in Medicare beneficiaries in nursing homes with Alzheimer’s disease and related dementias. J Am Geriatr Soc. 2015;63(9):1757–65. doi:10.1111/jgs.13606.

    Article  PubMed  Google Scholar 

  33. Sahlberg M, Holm E, Gislason GH, et al. Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons. J Am Heart Assoc. 2015;4(9):e001666. doi:10.1161/JAHA.114.001666.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bozat-Emre S, Doupe M, Kozyrskyj AL, et al. Atypical antipsychotic drug use and falls among nursing home residents in Winnipeg, Canada. Int J Geriatr Psych. 2015;30(8):842–50. doi:10.1002/gps.4223.

    Article  Google Scholar 

  35. Simoni-Wastila L, Wei YJ, Lucas JA, et al. Mortality risk of antipsychotic dose and duration in nursing home residents with chronic or acute indications. J Am Geriatr Soc. 2016;64(5):973–80. doi:10.1111/jgs.14111.

    Article  PubMed  Google Scholar 

  36. Berry SD, Placide SG, Mostofsky E, et al. Antipsychotic and benzodiazepine drug changes affect acute falls risk differently in the nursing home. J Gerontol A Biol Sci Med Sci. 2016;71(2):273–8. doi:10.1093/gerona/glv091.

    Article  PubMed  Google Scholar 

  37. Wei YJ, Simoni-Wastila L, Lucas JA, Brandt N. Fall and fracture risk in nursing home residents with moderate-to-severe behavioral symptoms of Alzheimer’s disease and related dementias initiating antidepressants or antipsychotics. J Gerontol A Biol Sci Med Sci. 2016;. doi:10.1093/gerona/glw095 (Epub ahead of print).

    PubMed  Google Scholar 

  38. Park Y, Franklin JM, Schneeweiss S, et al. Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. J Am Geriatr Soc. 2015;63(3):516–23. doi:10.1111/jgs.13326.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305–17. doi:10.1046/j.1532-5415.2003.51417.x.

    Article  PubMed  Google Scholar 

  40. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;. doi:10.1002/14651858.CD003476.pub2.

    PubMed  Google Scholar 

  41. Lonergan E, Luxenberg J, Sastre AA. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009;. doi:10.1002/14651858.CD006379.pub3.

    Google Scholar 

  42. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;. doi:10.1002/14651858.CD008191.pub2.

    PubMed  Google Scholar 

  43. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;. doi:10.1002/14651858.CD004990.

    PubMed  Google Scholar 

  44. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014;. doi:10.1002/14651858.CD009178.pub2.

    PubMed  Google Scholar 

  45. Bourgeois J, Elseviers MM, Van Bortel L, et al. Sleep quality of benzodiazepine users in nursing homes: a comparative study with nonusers. Sleep Med. 2013;14(7):614–21. doi:10.1016/j.sleep.2013.03.012.

    Article  PubMed  Google Scholar 

  46. Bourgeois J, Elseviers MM, Van Bortel L, et al. One-year evolution of sleep quality in older users of benzodiazepines: a longitudinal cohort study in Belgian nursing home residents. Drug Aging. 2014;31(9):677–82. doi:10.1007/s40266-014-0203-3.

    Article  CAS  Google Scholar 

  47. Bourgeois J, Elseviers MM, Van Bortel L, et al. The impact of chronic benzodiazepine use on cognitive evolution in nursing home residents. Hum Psychopharm Clin. 2015;30(2):85–93. doi:10.1002/hup.2456.

    Article  CAS  Google Scholar 

  48. Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;. doi:10.1002/14651858.CD007726.pub2.

    PubMed  Google Scholar 

  49. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213–8. doi:10.1159/000101499.

    PubMed  Google Scholar 

  50. Chiu YW, Bero L, Hessol NA, et al. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015;119(6):802–13. doi:10.1016/j.healthpol.2015.02.014.

    Article  PubMed  Google Scholar 

  51. Maust DT, Kim H, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45. doi:10.1001/jamapsychiatry.2014.3018.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gardette V, Lapeyre-Mestre M, Coley N, et al. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients: evidence for a role of dementia severity. Curr Alzheimer Res. 2012;9(9):1106–16.

    Article  CAS  PubMed  Google Scholar 

  53. Danielsson B, Collin J, Bergman GJ, et al. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults: a Swedish nationwide study. Br J Clin Pharmacol. 2016;81(4):773–83. doi:10.1111/bcp.12829.

    Article  CAS  PubMed  Google Scholar 

  54. Foebel AD, Onder G, Finne-Soveri H, et al. Physical restraint and antipsychotic medication use among nursing home residents with dementia. J Am Med Dir Assoc. 2016;17(2):184.e9–14. doi:10.1016/j.jamda.2015.11.014.

    Article  Google Scholar 

  55. de Groot MH, van Campen JPCM, Moek MA, et al. The effects of fall-risk-increasing drugs on postural control: a literature review. Drug Aging. 2013;30(11):901–20. doi:10.1007/s40266-013-0113-9.

    Article  CAS  Google Scholar 

  56. Ballokova A, Peel NM, Fialova D, et al. Use of benzodiazepines and association with falls in older people admitted to hospital: a prospective cohort study. Drug Aging. 2014;31(4):299–310. doi:10.1007/s40266-014-0159-3.

    Article  CAS  Google Scholar 

  57. Sterke CS, Ziere G, van Beeck EF, et al. Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol. 2012;73(5):812–20. doi:10.1111/j.1365-2125.2011.04124.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Moulis F, Moulis G, Balardy L, et al. Exposure to atropinic drugs and frailty status. J Am Med Dir Assoc. 2015;16(3):253–7. doi:10.1016/j.jamda.2014.11.017.

    Article  PubMed  Google Scholar 

  59. Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51(3):606–13. doi:10.1016/j.bone.2012.05.018.

    Article  CAS  PubMed  Google Scholar 

  60. Souchet E, Lapeyre-Mestre M, Montastruc JL. Drug related falls: a study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2005;14(1):11–6. doi:10.1002/pds.1038.

    Article  PubMed  Google Scholar 

  61. Trifiró G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. Drug Saf. 2014;37(7):501–20. doi:10.1007/s40264-014-0170-y.

    Article  PubMed  Google Scholar 

  62. Gambassi G, Sultana J, Trifirò G. Antipsychotic use in elderly patients and the risk of pneumonia. Exp Opin Drug Saf. 2015;14(1):1–6. doi:10.1517/14740338.2015.984684.

    Article  CAS  Google Scholar 

  63. Nosè M, Recla E, Trifirò G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2015;24(8):812–20. doi:10.1002/pds.3804.

    Article  PubMed  Google Scholar 

  64. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183–92. doi:10.1007/s40266-013-0056-1.

    Article  CAS  PubMed  Google Scholar 

  65. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332–40. doi:10.1183/09031936.00008014.

    Article  CAS  PubMed  Google Scholar 

  66. Jalbert JJ, Daiello LA, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am J Geriatr Pharmacother. 2011;9(3):153–63. doi:10.1016/j.amjopharm.2011.04.006.

    Article  CAS  PubMed  Google Scholar 

  67. Laroche ML, Perault-Pochat MC, Ingrand I, et al. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf. 2013;22(9):952–60. doi:10.1002/pds.3471.

    CAS  PubMed  Google Scholar 

  68. Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drug Aging. 2014;31(3):159–84. doi:10.1007/s40266-014-0152-x.

    Article  CAS  Google Scholar 

  69. Aparasu RR, Chatterjee S, Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother. 2013;47(4):464–74. doi:10.1345/aph.1R510.

    Article  PubMed  Google Scholar 

  70. Bali V, Chatterjee S, Johnson ML, et al. Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016;5(5):461–73. doi:10.2217/cer-2016-0009.

    Article  PubMed  Google Scholar 

  71. Chatterjee S, Carnahan RM, Chen H, et al. Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study. J Am Geriatr Soc. 2016;64(2):394–400. doi:10.1111/jgs.13932.

    Article  PubMed  Google Scholar 

  72. Gallini A, Donohue JM, Huskamp HA. Diffusion of antipsychotics in the U.S. and French markets, 1998–2008. Psychiat Serv. 2013;64(7):680–7. doi:10.1176/appi.ps.004662012.

    Article  Google Scholar 

  73. Schulze J, van den Bussche H, Glaeske G, et al. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur Neuropsychopharm. 2013;23(9):1034–42. doi:10.1016/j.euroneuro.2013.02.001.

    Article  CAS  Google Scholar 

  74. Gallini A, Andrieu S, Donohue JM, et al. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharm. 2014;24(1):95–104. doi:10.1016/j.euroneuro.2013.09.003.

    Article  CAS  Google Scholar 

  75. Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015;25(10):1566–77. doi:10.1016/j.euroneuro.2015.07.006.

    Article  CAS  PubMed  Google Scholar 

  76. Nørgaard A, Jensen-Dahm C, Gasse C, et al. Time trends in antipsychotic drug use in patients with dementia: a nationwide study. J Alzheimers Dis. 2015;49(1):211–20.

    Article  PubMed  Google Scholar 

  77. Sultana J, Fontana A, Giorgianni F, et al. The effect of safety warnings on antipsychotic drug prescribing in elderly persons with dementia in the United Kingdom and Italy: a population-based study. CNS Drugs. 2016;. doi:10.1007/s40263-016-0366-z.

    PubMed  Google Scholar 

Download references

Acknowledgements

The author thanks Nathalie Bel, librarian at the UMR Inserm 1027 (Research Unit of Public Health, University of Toulouse, France) for her contribution to the literature searching and for providing full texts of the articles. The author also expresses her gratitude to Felicie Pastore, Honorary Professor of Medical English, for her helpful contribution in editing the manuscript.

Author information

Authors and Affiliations

  1. Clinical Pharmacology Department, Clinical Investigation Centre (CIC1436), Research Unit of Pharmacoepidemiology (UMR Inserm 1027), University of Toulouse, 37 Allees Jules Guesde, Toulouse, 31000, France

    Maryse Lapeyre-Mestre

Authors
  1. Maryse Lapeyre-Mestre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maryse Lapeyre-Mestre.

Ethics declarations

Funding

The author did not receive any financial support to do this work.

Conflict of interest

The author does not report any conflict of interest in relation to this work.

Ethical Standards

As a literature review focusing on observational studies, this work complies with ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lapeyre-Mestre, M. A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia. Drugs Aging 33, 865–888 (2016). https://doi.org/10.1007/s40266-016-0414-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-016-0414-x

Keywords

Search

Navigation